Lupin Introduces Thiamine Hydrochloride Injection USP in US markets

Global pharma major Lupin Limited (Lupin) announced the launch of thiamine hydrochloride injection USP, 200 mg/2 mL (100 mg/mL) multiple-dose vials, after Lupin’s alliance partner Caplin Steriles Limited (Caplin) received an approval for its ANDA from the United States Food and Drug Administration (FDA). This comes after Lupin’s alliance partner Caplin Steriles Limited (Caplin) received approval for its ANDA from the United States Food and Drug Administration (U.S. FDA). In the United States, IQVIA MAT April 2023 anticipated annual sales of USD 35 million for thiamine hydrochloride injection USP.

Thiamine Hydrochloride Injection USP, 200 mg/2 mL (100 mg/mL) Multiple-dose Vials, according to the firm, is therapeutically similar to Fresenius Kabi USA LLC's reference listed drug (RLD), Thiamine Hydrochloride Injection USP, 200 mg/2 mL (100 mg/mL). Lupin is a worldwide pharmaceutical firm based in Mumbai, India that focuses on innovation. The company develops and commercialises a diverse range of branded and generic formulations, biotechnology products, and APIs in over 100 markets worldwide, including the United States, India, South Africa, and Asia Pacific (APAC), Latin America (LATAM), Europe, and the Middle East.